Interview with Thierry Poiraud, General Manager, Menarini France
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
Address: Menarini Building 1 rue du Jura 94633 Rungis Cedex BP 40528, France
Tel: 01 45 60 77 20
Web: http://www.menarini.fr/accueil/
Menarini started up its operations in Feb 1992 with a product portfolio acquired through an exchange of products with Sanofi. From this base, the affiliate ventured onto the French market and in 1993 it launched an original gel with analgesic and anti-inflammatory properties, and in a few months time it became the leader in this therapeutic class. Three innovative cardiovascular products have been launched successively in 2002 and 2004.
MENARINI, 1 Italian pharmaceutical group, today operates in over 100 countries. With over 2.6 billion euros in turnover, 12 500 employees, the Menarini Group is the 20th in European rankings and 36th in the world rankings.
France: 112.5 million euros in 2008; employs 600 (heavy growth in last 5 years, double # last 3 years and wants 150m euro for 2010)
Distribution of turnover: 30% Self-Medication – Ethical Drugs 70%
Commercial/Mkting autonomy for HQ
2 launches in 2009: cardiology, angina pectoris
Sports medicine and Rhumatology in France
Present in the most important therapeutic areas of greatest importance, including:
• Cardiovascular Products
• Gastro-intestinal Products
• Antibiotics / Respiratory System Products
• Diabetes
• Anti-inflammatory agents / Analgesics
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market…
The CEO of Diaxonhit Group, a fully integrated French leader in in vitro diagnostics, discusses the company’s strategic focus on specialty vitro diagnostics, his perspective on the challenge of consolidation…
The Vice President of Health and Medicine at Pierre and Marie Curie University (UPMC) and Director of the University’s Institute of Oncology reveals how the French social security system needs…
The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting…
The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership…
Pierre Banzet, President of Group Synerlab, one of the top ten French CMOs, discusses his group’s ambitious European expansion strategy, driven by their specialties in multi-dose, preservative-free eye drops, generics,…
The Director of the newly formed Necker Institute for Sick Children reveals how the inspiration behind INEM was to bring people together in order to create a common scientific policy…
Pfizer Global Established Products’ BU Head and Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well…
The Head of the Department of Medical Oncology at the Pitié-Salpêtrière Hospital reveals how France is the only country in the world with universal and unlimited access to healthcare, how…
(© Sébastien Borda) The CEO of Novartis France reveals how the construction of a new French headquarters demonstrates a commitment to develop operations in the country, how the Huningue Biotechnology…
The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair…
See our Cookie Privacy Policy Here